
Menarini Group Presents New Data on ORSERDU® (Elacestrant) for ER+, HER2- Advanced Metastatic Breast Cancer at 2024 SABCS
The Menarini Group, a global leader in pharmaceuticals and diagnostics, along with its subsidiary Stemline Therapeutics, will present new and expanded data on ORSERDU® (elacestrant) at the 2024 San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. The company…












